This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Best Stocks to Watch in '11


@jacobskip tweets, "What do you think about ACTC? Is Socius funding kiss of death? Have any additional information to share on Socius/Peizer?"

This was in response to a tweet of mine pointing out that Advanced Cell Technologies (ACTC.OB) nabbed $25 million in funding from Socius Capital Group. Sounds innocuous enough, but Socius is chaired by Terren Peizer, the founder and CEO of Hythiam (HYTM.OB), peddlers of the controversial Prometa addiction treatment program. Peizer claims Prometa is a revolutionary new way for addicts to kick the habit. Critics accuse Peizer of selling snake oil. I suggest checking out Hythiam's stock chart over the past few years before deciding which side is right.

Now, Advanced Cell's embryonic stem cell research has nothing to do with Hythiam or treating drug addicts. However, if Advanced Cell's stem cell technology is as revolutionary as its founders claim, why does the stock trade on the bulletin boards, and why does the company need to seek out funding from someone as controversial as Peizer?

Socius has an "impressive record of making investments in emerging life scienes companies," said Advanced Cell in its funding announcement. I checked Socius' recent filings with the Securities and Exchange Commission and found that the firm's investment holdings include Muscle Pharm (MLSP.OB), New Generation Biofuels Holdings (NGPF.PK), PositiveID (PSID), Dutch Gold Resources (DGRI.PK), International Stem Cell (ISCO.OB), DayStar Technologies (DSTI) and ZBB Energy (ZBB), among others.

Advanced Cell, even trading for 20 cents a share, has an enterprise value of $250 million because the company has 1.3 billion shares outstanding! Traders likely consider a 20-cent stock to be cheap and love that the company issues press releases all day long to keep the stock liquid. For those of us who look at fundamentals and balance sheets, a $250 million enterprise value for a high-risk company like Advanced Cell is really expensive.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
4 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs